The influence of ageing on the development and management of rheumatoid arthritis

Annemieke M.H. Boots, Andrea B. Maier, Piet Stinissen, Pierre Masson, Rik J. Lories, Filip De Keyser*

*Corresponding author for this work

Research output: Contribution to JournalReview articleAcademicpeer-review

Abstract

The population of elderly individuals with rheumatoid arthritis (RA) is expanding, due mainly to increasing life expectancy. A variety of theories have been proposed to explain the ageing process, including accumulation of DNA damage and resultant changes in biological processes. Such changes can influence the development and/or course of disease. Furthermore, alterations in biological function determine the biological age-as opposed to chronological age-of an individual, which strongly influences their ability to cope with disease. Moreover, comorbidities are more frequent in elderly individuals. Together, these factors complicate treatment of disease and necessitate careful patient management. Indeed, although evidence from clinical trials suggests that DMARDs and biologic agents have good efficacy and are well tolerated in elderly patients with RA, such individuals are often undertreated and inadequately managed. Unfortunately, insufficient data are available for the development of evidence-based guidelines for this population, as elderly patients are often excluded from clinical trials owing to age restrictions or comorbidities. Thus, additional clinical studies in elderly patients are warranted, with treatment regimens tailored according to vitality or frailty parameters. This Review focuses on the pathophysiological aspects of ageing and their implications for the management of RA in elderly patients.

Original languageEnglish
Pages (from-to)604-613
Number of pages10
JournalNature Reviews Rheumatology
Volume9
Issue number10
DOIs
Publication statusPublished - 18 Jun 2013

    Fingerprint

Cite this